Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

Pathogen inactivation systems are in use in many European countries as routine procedures. However, a pathogen inactivation system for erythrocytes is currently not available. Although significant improvements have been made to decrease the incidence of transfusion-transmitted infections, risks remain for infectious disease agents specific to red blood cell concentrates, such as parasitic infections resulting in babesiosis and malaria. The pathogen inactivation system for erythrocytes utilizes S-303 and glutathione for the treatment of red blood cell concentrates. Preclinical studies to assess the pathogen inactivation efficacy and toxicology as well as preliminary clinical studies have been completed. Preclinical studies have shown log reduction for leukocytes, several viruses and bacteria in excess of 4 to 6 logs. Preclinical toxicology studies were conducted to enable the initiation of two phase III clinical studies in the USA for support of acute and chronic anemia. A second-generation system was developed after observation of an unexpected immune response in two chronic anemia patients. Preclinical pathogen inactivation studies, serological evaluations and a clinical study to evaluate survival of S-303-treated erythrocytes have been completed to support advanced development of the S-303 pathogen inactivation system. A functional system for the inactivation of red blood cell concentrates has been completed and is reaching clinical application.

[1]  J. Cazenave,et al.  Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period , 2011, Transfusion.

[2]  S. Sandler.  The status of pathogen-reduced plasma. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[3]  P. Mintz,et al.  A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology , 2010, Transfusion.

[4]  M. Busch,et al.  Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress , 2010, Transfusion.

[5]  P. Ness.  The curtain is still going up , 2010, Transfusion.

[6]  A. Mast,et al.  Community blood donors' knowledge of anemia and design of a literacy‐appropriate educational intervention , 2010, Transfusion.

[7]  M. Steiner,et al.  Does red blood cell storage affect clinical outcome? When in doubt, do the experiment , 2009, Transfusion.

[8]  Qun Lu,et al.  Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug‐induced nonimmunologic protein adsorption , 2009, Transfusion.

[9]  E. Moore,et al.  Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. , 2009, Blood.

[10]  R. Zimmermann,et al.  Influence of prestorage leukoreduction and subsequent irradiation on in vitro red blood cell (RBC) storage variables of RBCs in additive solution saline‐adenine‐glucose‐mannitol , 2009, Transfusion.

[11]  G. Garratty,et al.  Serological studies of piperacillin antibodies , 2008, Transfusion.

[12]  J. Muñoz-Jordán,et al.  Dengue virus in blood donations, Puerto Rico, 2005 , 2008, Transfusion.

[13]  F. Luciani,et al.  External quality assessment for the detection of HCV RNA, HIV RNA and HBV DNA in plasma by nucleic acid amplification technology: a novel approach , 2008, Vox Sanguinis.

[14]  L. Cardo,et al.  Neutrophil priming, caused by cell membranes and microvesicles in packed red blood cell units, is abrogated by leukocyte depletion at collection. , 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[15]  H. Alter.  Pathogen Reduction: A Precautionary Principle Paradigm , 2008, Transfusion Medicine Reviews.

[16]  H. Klein,et al.  Pathogen inactivation: making decisions about new technologies , 2007, Transfusion.

[17]  Anne Aupérin,et al.  Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study , 2007, Transfusion.

[18]  R. Benjamin,et al.  The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two‐bottle culture systems and an estimation of false‐negative culture rates , 2007, Transfusion.

[19]  J. George,et al.  A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura , 2006, Transfusion.

[20]  L. Corash,et al.  Viability of red cells prepared with S‐303 pathogen inactivation treatment , 2006, Transfusion.

[21]  L. Sawyer,et al.  Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function , 2006, Transfusion.

[22]  D. Jukic,et al.  Fatal transfusion‐associated graft‐versus‐host disease in an immunocompetent recipient of a volunteer unit of red cells , 2006, Transfusion.

[23]  P. Mintz,et al.  Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. , 2006, Blood.

[24]  D. Leiby.  Babesiosis and blood transfusion: flying under the radar , 2006, Vox sanguinis.

[25]  P. Mintz,et al.  Therapeutic efficacy and safety of red blood cells treated with a chemical process (S‐303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients , 2005, Transfusion.

[26]  H. Reesink,et al.  Professor J. J. van Loghem , 2005 .

[27]  J. Cazenave,et al.  Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set , 2005, Transfusion.

[28]  S. Sloan,et al.  Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion. , 2004 .

[29]  B. Molini,et al.  Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria , 2004, Transfusion.

[30]  G. Garratty,et al.  A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies , 2004, Transfusion.

[31]  J. Fridey,et al.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. , 2004, Blood.

[32]  A. Brand,et al.  HLA and RBC immunization after filtered and buffy coat‐depleted blood transfusion in cardiac surgery: a randomized controlled trial , 2003, Transfusion.

[33]  M. Boeckh,et al.  Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. , 2003, Blood.

[34]  P. Ljungman,et al.  Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. , 2003, Blood.

[35]  E. Vamvakas,et al.  Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? , 2001, Blood.

[36]  S. Leitman,et al.  Principles of blood irradiation, dose validation, and quality control , 1997, Transfusion.

[37]  L. Griffith,et al.  A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions , 1993, Transfusion.

[38]  M. Mathru.  An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions , 2012 .

[39]  L. Sawyer,et al.  Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. , 2010, Biologicals : journal of the International Association of Biological Standardization.